Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Huahai Already Developed New Manufacturing Process for Valsartan API, Says Japan Chief after JMA Criticism on Impurity Issue
September 6, 2018
- Sawai’s Abilify Generic Approved for Bipolar Disorder
September 6, 2018
- Lenvima Gets China OK for 1st Line HCC: Eisai/Merck
September 6, 2018
- I/O in Lung Cancer - 4: Bristol-Myers Looks to Regain Ground for Opdivo with Immunotherapy Combos
September 5, 2018
- FDA Snubs Sunovion’s ADHD Drug
September 4, 2018
- Life Science Institute to Initiate Exploratory Clinical Study of Muse Cell Product for Cerebral Infarction
September 4, 2018
- Thrombocytopenia Drug Mulpleta Now Available in US: Shionogi
September 3, 2018
- Yamaha Motor to Invest in Biotech Evec to Strengthen Presence in Biomedical Field
September 3, 2018
- Taisho’s Voluntary Early Retirement Program Attracts 948 Applicants
September 3, 2018
- Kowa’s Parmodia Most Heavily Pitched for GPs in June: Anterio
August 31, 2018
- Global Biologic Market Rises 13.9% to 18.6 Trillion Yen in FY2017 Driven by I/O Drugs
August 31, 2018
- With Bullish Maviret, AbbVie Aims for Double-Digit Growth to Join Top 20 in 2018
August 30, 2018
- South Korea OKs Lenvima for 1st Line HCC: Eisai
August 30, 2018
- Eisai/Biogen’s Alzheimer’s Drug Aducanumab Shows Continued Efficacy in Long-Term Extension PIb Study
August 30, 2018
- Imfinzi, Gazyva Now Available in Japan
August 30, 2018
- Celltrion Launches Herceptin Biosimilar in Japan
August 29, 2018
- Ono Hooks Up with BMS, Clovis to Develop Opdivo/Rucaparib Combo Therapy in Japan, S. Korea, Taiwan
August 29, 2018
- I/O in Lung Cancer - 3: Pfizer Sets Sights on Ovarian Cancer after NSCLC Trial Fails
August 28, 2018
- Gilead Japan Looks to End HIV Pacts with JT as It Seeks Long-Term Growth: Chief
August 28, 2018
- New AG Re-Pricing Rule Erodes 10 Billion Yen from Daiichi Sankyo Espha Sales
August 28, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…